179 related articles for article (PubMed ID: 35292161)
21. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence.
Chilson E; Scott DA; Schmoele-Thoma B; Watson W; Moran MM; Isturiz R
Hum Vaccin Immunother; 2020 Nov; 16(11):2758-2772. PubMed ID: 32530360
[TBL] [Abstract][Full Text] [Related]
23. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Advisory Committee on Immunization Practices
MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions.
Kobayashi M; Stoecker C; Xing W; Cho BH; Pilishvili T
Hum Vaccin Immunother; 2021 Jul; 17(7):2232-2240. PubMed ID: 33499718
[TBL] [Abstract][Full Text] [Related]
26. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Kobayashi M; Farrar JL; Gierke R; Leidner AJ; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL; ;
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1174-1181. PubMed ID: 36107786
[TBL] [Abstract][Full Text] [Related]
27. Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population.
Alvarez CA; Hall RG; Lin S; Perkins AR; Mortensen EM
Vaccine; 2024 Jan; 42(3):489-495. PubMed ID: 38177030
[TBL] [Abstract][Full Text] [Related]
28. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.
Vila-Corcoles A; Ochoa-Gondar O; Hospital I; de Diego C; Satué E; Bladé J; Ansa X; Guzmán JA; Salsench E; Ramos F
Hum Vaccin Immunother; 2016 Nov; 12(11):2953-2958. PubMed ID: 27454779
[TBL] [Abstract][Full Text] [Related]
29. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
[TBL] [Abstract][Full Text] [Related]
30. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017.
Vila-Córcoles A; Ochoa-Gondar O; de Diego C; Satué E; Vila-Rovira A; Aragón M
Euro Surveill; 2019 Jul; 24(29):. PubMed ID: 31339099
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.
Smith KJ; Nowalk MP; Raymund M; Zimmerman RK
Vaccine; 2013 Aug; 31(37):3950-6. PubMed ID: 23806240
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
[TBL] [Abstract][Full Text] [Related]
33. Call to action on pneumococcal disease: review of vaccination evidence and outcomes of webcast programs.
Grogg SE; Schultz J
J Am Osteopath Assoc; 2015 Jun; 115(6 Suppl):S6-25. PubMed ID: 26000904
[TBL] [Abstract][Full Text] [Related]
34. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
[TBL] [Abstract][Full Text] [Related]
35. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
[TBL] [Abstract][Full Text] [Related]
37. Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines.
Pilishvili T; Bennett NM
Vaccine; 2015 Nov; 33 Suppl 4():D60-5. PubMed ID: 26116257
[TBL] [Abstract][Full Text] [Related]
38. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
Ludwig E; Mészner Z;
Orv Hetil; 2014 Dec; 155(50):1996-2004. PubMed ID: 25481502
[TBL] [Abstract][Full Text] [Related]
39. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
Buchwald UK; Andrews CP; Ervin J; Peterson JT; Tamms GM; Krupa D; Ajiboye P; Roalfe L; Krick AL; Sterling TM; Wang M; Martin JC; Stek JE; Kohn MA; Folaranmi T; Abeygunawardana C; Hartzel J; Musey LK;
Hum Vaccin Immunother; 2021 Aug; 17(8):2678-2690. PubMed ID: 34019468
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
